-
Br J Cancer: APC deficiency induces the Warburg effect of colorectal cancer cells by mediating the Wnt/β-catenin/PKM2 path.
Time of Update: 2020-10-29
the study sheds light on the key link between the Warburg effect and the abnormally activated Wnt/β-catenin signal transductive path, particularly in colorectal cancer (CRC), where APC (adenoma-related gene associated with colon pliosarcoma) is defunct.
-
NEJM: Dasatini-Bona Twain anti-treatment Philadelphia chromosome-positive acute lymphoblastic leukemia.
Time of Update: 2020-10-29
study concluded that for Philadelphia chromosomal-positive acute lymphoblastic leukemia, dassatinib, glucosal hormone combined with Bonatoda monoantimmune therapy can induce patients to have a sustained molecular response, to obtain a higher survival rate.
-
Nat Commun: Significant progress! Cai Junchao/Wu Wei of Sun Yat-sen University has discovered new potential therapeutic targets for lung adenocarcinoma.
Time of Update: 2020-10-29
October 12, 2020, Sun Yat-sen University's Cai Junchao and Wu Wei jointly published a research paper entitled "AKT-induced lncRNA VAL promotes EMT-metastasis through development Trim 16-dependent Vimentin" online, based on a study induced by AKT Long non-coding RNA (lncRNA) analysis has identified VAL (waveform protein-related lncRNA, LINC01546) directly induced by AKT/STAT3 signals as an effective pro-transfer molecule and is essential for tumor immersion, metastasis and nerve-free tolerance of active AKT-induced pulmonary adenocarcinoma (LAD).
-
Br J Cancer: International Cohort Study: Effects of Age on the Prognosis of Solafini's Treatment of Hepatocellular Carcinoma.
Time of Update: 2020-10-29
Kaplan-Meier methodology estimated the total survival rate of different sorafeini starting doses In the cohort study recruited a total of 5,598 patients, of whom 792 (14.1%) were ≥75-year-olds.
-
Lancet respir med: Pembrolizumab combined radiotherapy is used for the treatment of patients with metastasis non-small cell lung cancer.
Time of Update: 2020-10-29
In PEMBRO-RT (Phase 2) and MDACC (Phase 1/2) trials, patients with metastasis non-small cell lung cancer were randomly assigned to receive immunotherapy (Pembrolizumab) with or without radiotherapy, the researchers published the results of the study.
-
Science Advances : Significant progress! For the first time, Yu Ying of Shanghai University of Science and Technology has established genetic evidence of cardiovascular risk caused by anti-tumor drugs.
Time of Update: 2020-10-29
, the findings establish a link between causal allegens of cardiovascular disease genes and pharmacological regulation, which can facilitate the discovery of cancer drugs and clinical trial design.
the study established a compilation of genetic evidence to support the risk of cardiovascular disease caused by anti-tumor drugs.
-
Fda approves FoundationOne CDx as an accompanying diagnostic agent for Vitrakvi (larotrectinib) to help identify NTRK fusion-positive patients.
Time of Update: 2020-10-29
. Bayer recently announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®CDx as the first accompanying diagnostic method to help identify patients who may be suitable for neurotrophic ligenics Tyrosine kinase (NTRK) fusion that may be suitable for treatment with Vitrakvi® One CDx is an FDA-approved Comprehensive Genomic Analysis (CGP) test for all solid tumors.
-
AstraZenecon's EGFR inhibitor osimertinib assists in the treatment of non-small cell lung cancer and is given FDA priority review.
Time of Update: 2020-10-28
AstraZeneca's EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been given priority review by the U.S. Food and Drug Administration (FDA) for complementary treatment in patients with early (Ib, II, IIIA) non-small cell lung cancer (NSCLC) mutations after surgical removal.
-
Nat Commun: AP-1 and TGF beta co-mediate the resistance of non-classical Hedgehog signal transducting paths to induce substrate cell carcinoma.
Time of Update: 2020-10-28
the transcription of RHoGEFs induced by AP-1 and Smad3, the researchers identified three prognostic surface markers (LYPD3, TACSTD2, and LY6D) associated with nMRTF and SMO inhibitor resistance by sequencing single-cell RNA in patient tumor tissue.
-
Clin Cancer Res: Tucatinib has been approved to treat advanced HER2-positive breast cancer.
Time of Update: 2020-10-28
On April 17, 2020, the FDA approved tucatinib co-curtoju single resistance and carpestabin treatment for patients with advanced breast cancer who are non-surgically removable or metastasis HER2-positive, including those who have received one or more anti-HER2-based programs after metastasis.
-
Nat Med: A new breakthrough in immunotherapy! Human experimental data reveal the potential of CAR-NKT therapy to treat solid tumors.
Time of Update: 2020-10-28
The interim report, a phase 1 clinical trial conducted by researchers at Baylor College of Medicine and the University of North Carolina at Chapel Hill, suggests that genetically modified GD2-specific CAR (embedded antigens) that enable human NKT cell expression to specifically identify and attack neuroblastoma (NB) and leucocyte mesotonin-15 (IL-15), which supports the survival of NKT cells, may be important tools in the fight against cancer.
-
Cell Death Dis:SPATS2 regulates cell cycles to promote the development of liver cancer.
Time of Update: 2020-10-28
study on miR-145-5p/SPATS2 pathology in HCC to regulate apoptosis and cell cycles aims to reveal the expression spectrum and functional role of SPATS2 in liver cancer, and to explore the related regulatory role of SPATS2.
-
PNAS: Probiotics work! Wang Feng's team reported that Bifidobacteria can alleviate the side effects of cancer immunotherapy.
Time of Update: 2020-10-28
the study found that Bifidobacteria can optimize the composition of symblotic bacteria under the condition of CTLA-4 blocking at the immuno checkpoint, and enhance the function and metabolism of intestinal regulatory T-cells (Treg), thereby alleviating anti-CTLA-4 antibody-induced intestinal inflammation.
-
Br J Cancer: LncRNA HOTAIR promotes the invasion and metastasis of prostate cancer by targeting hepaCAM.
Time of Update: 2020-10-28
further studies have shown that HOTAIR induces abnormal activation of high-level H3K27me3 modifications and MAPK paths by raising PRC2 to the hepaCAM promoter, ultimately inhibiting the expression of hepaCAM.
, the study shows that HOTAIR can promote PCa invasive and metastasis by reducing the inhibition of hepaCAM on the MAPK signal transducting path.
-
Will inflammation become cancer after a long time? Doctors remind: 4 places in the body inflamed, to seek medical attention as soon as possible.
Time of Update: 2020-10-28
according to the study, the incidence of chronic pharyngitis and rhinitis in China is about 87%, the incidence of chronic gastritis is 30%, and the incidence of various chronic kidney diseases is 11%, and the incidence of these inflammations is increasing year by year.
-
The FDA is about to approve the liquid biopsy technology Parsortix for metastasis breast cancer.
Time of Update: 2020-10-28
Liquid biopsy company ANGLE recently announced that the U.S. Food and Drug Administration (FDA) has conducted a substantive review of the application of the liquid biopsy technology Parsortix for patients with metastasis breast cancer (MBC).
-
Blood: Increased risk of thromboembolism in cancer patients treated with immuno-checkpoint inhibitors!
Time of Update: 2020-10-28
: Currently, the risk of venous and arterial thromboembolism (VTE/ATE) associated with immuno checkpoint inhibitors is not fully identified, and clinical trials to evaluate such drugs in cancer patients do not provide relevant information.
-
J Clin Oncol: Phase III SORCE . Soraphinist cannot be used as a postoperative ancillary treatment for primary kidney cancer with a medium to high risk of recurrence.
Time of Update: 2020-10-28
SORCE is an international, randomized, double-blind three-arm trial that evaluates the effectiveness of Solaffini's complementary therapy in patients with primary renal cell carcinoma (RCC) who are at a medium to high risk of recurrence after surgical excision.
-
Brit J Cancer: Effects of age on outcomes in patients with soraphini to treat hepatocellular carcinoma.
Time of Update: 2020-10-28
recently, a study published in British Journal of Cancer, an authoritative journal in the field of oncology, was designed to assess whether age affects total survival (OS) and whether lowering the starting dose affects OS or toxicity in older adults.
-
Nat Commun: Detection of early pancreatic cancer with free DNA.
Time of Update: 2020-10-28
Recently, researchers in Nature Communications described changes in circulating cell free DNA through 5-hydroxymed methyl cytosine (5hmC), non-invasive detection of pancreatic catheter cancer (PDAC) in PDAC queues (n s 64) and non-cancer queues (n s 243).
results suggest that PDAC can be classified based on changes in 5hmC even during early disease.
